Clinicopathologic and prognostic significance of human epidermal growth factor receptor in patients with gastric cancer: An updated meta-analysis
Metrics: PDF 718 views | HTML 812 views | ?
Zhiqiao Zhang1,3,*, Hongfeng Tang2, Jixin Lin3, Yunzhao Hu1,3,**, Guanying Luo1,3,*, Zhaowen Luo3, Canchang Cheng1,3, Peng Wang1,3
1Department of Infectious Disease, The First People’s Hospital of Shunde, Shunde, Guangdong, China
2Department of Science and Education, The First People’s Hospital of Shunde, Shunde, Guangdong, China
3Department of Internal Medicine, The Chencun Hospital Affiliated to The First People’s Hospital of Shunde, Shunde, Guangdong, China
*These authors contributed equally to this study and were co-first authors
**This author as a joint corresponding author contributed equally to this study as Peng Wang
Peng Wang, email: email@example.com
Keywords: gastric cancer, human epidermal growth factor receptor, meta-analysis, prognostic significance
Abbreviations: Gastric cancer GC; human epidermal growth factor receptor EGFR; odds ratio OR; hazard ratio HR; confidence interval CI
Received: July 11, 2016 Accepted: January 06, 2017 Published: February 09, 2017
Purpose: The aim of this update meta-analysis was to clarify the clinicopathologic and prognostic significance of human epidermal growth factor receptor(EGFR) expression in gastric cancer patients.
Experimental Design: Several electronic databases were searched from January 1970 to May 2016. The odds ratio (OR) was calculated to assess the association between EGFR expression and pathological parameters. The hazard ratio (HR) and 95% CI were calculated to explore the relationship between EGFR expression and overall survival.
Results: Finally 7229 patients with gastric cancer from 25 eligible studies were included in the present meta analysis. High EGFR expression was found to be significantly related with tumor differentiation (OR=1.96, 95%CI: 1.14-3.34, Z=2.43, P=0.015), lymph node metastasis (OR=2.20, 95% CI: 1.63-2.96, Z=5.17, P=0.001), and tumor stage (OR=2.13, 95% CI: 1.35-3.36, Z=3.25, P=0.001). However, high EGFR expression was not significantly associated with invasion depth (OR=2.09, 95% CI: 0.4-11.05, Z=0.87, P=0.385). The pooled HR suggested that high EGFR expression was significantly correlated with overall survival (HR=1.19, 95% CI 1.04-1.37, Z=2.44, P=0.015).
Conclusions: The present meta-analysis demonstrated that high EGFR expression significantly predicts poor prognosis, suggesting that high EGFR expression may serve as a predictive biomarker for poor prognosis in patients with gastric cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.